At the Fibrolamellar Cancer Foundation (FCF) Summit last month, Richard Cutler, Director of Translational Medicine at Puma Biotechnology, presented data on neratinib and its potential effectiveness in liver cancers.
Cutler is hopeful that neratinib, which was approved in the extended adjuvant setting in breast cancer in July, can provide clinical benefit to the rare liver cancer patient population and, in this video, he explains why.
Cutler: It goes into the ATP-binding pocket of the kinase domain of HER1, HER2 and HER4. It inhibits the ability of the protein kinase to transfer a phosphate, hence its activity, so I like to think of it as a very good mechanic in that it gets into the engine and blocks it very strongly.
On July 17, neratinib was approved in the extended adjuvant setting in breast cancer, which was very exciting. As part of the (FCF) Summit basket study, we’re looking at HER2 mutations in a number of different solid tumors, but in addition to that, we have a very active IST program – investigator sponsored trial program – where we’re looking at other indications, such as colorectal cancer, as well as other (cancer types).
Based on the fact that the EGF-receptor HER2 family is upregulated and activated and we have a very good HER2 family inhibitor, I feel like (neratinib) could have some efficacious potential. What we would like to see is tumor shrinkage, and we would like to see extended progression-free survival (PFS). That’s what we would like to see, but, again, you can’t really predict that.
For more from the Fibrolamellar Cancer Foundation, visit the organization’s website: fibrofoundation.org.